224 related articles for article (PubMed ID: 26443480)
1. Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma.
Oh JE; Ohta T; Nonoguchi N; Satomi K; Capper D; Pierscianek D; Sure U; Vital A; Paulus W; Mittelbronn M; Antonelli M; Kleihues P; Giangaspero F; Ohgaki H
Brain Pathol; 2016 Jul; 26(4):517-22. PubMed ID: 26443480
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components.
Actor B; Cobbers JM; Büschges R; Wolter M; Knobbe CB; Lichter P; Reifenberger G; Weber RG
Genes Chromosomes Cancer; 2002 Aug; 34(4):416-27. PubMed ID: 12112531
[TBL] [Abstract][Full Text] [Related]
3. Genetic profile of gliosarcomas.
Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
[TBL] [Abstract][Full Text] [Related]
4. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.
Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK
Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity on chromosome 19 in secondary glioblastomas.
Nakamura M; Yang F; Fujisawa H; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 2000 Jun; 59(6):539-43. PubMed ID: 10850866
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.
Fujisawa H; Reis RM; Nakamura M; Colella S; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 2000 Jan; 80(1):65-72. PubMed ID: 10653004
[TBL] [Abstract][Full Text] [Related]
7. Interphase cytogenetics of glioblastoma and gliosarcoma.
Paulus W; Bayas A; Ott G; Roggendorf W
Acta Neuropathol; 1994; 88(5):420-5. PubMed ID: 7847070
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.
Smith DR; Wu CC; Saadatmand HJ; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; Wang SH; Canoll P; McKhann GM; Wang TJC
J Neurooncol; 2018 Apr; 137(2):303-311. PubMed ID: 29264835
[TBL] [Abstract][Full Text] [Related]
9. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.
Cachia D; Kamiya-Matsuoka C; Mandel JJ; Olar A; Cykowski MD; Armstrong TS; Fuller GN; Gilbert MR; De Groot JF
J Neurooncol; 2015 Nov; 125(2):401-10. PubMed ID: 26354773
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetic alterations in glioblastomas with oligodendroglial component.
Kraus JA; Lamszus K; Glesmann N; Beck M; Wolter M; Sabel M; Krex D; Klockgether T; Reifenberger G; Schlegel U
Acta Neuropathol; 2001 Apr; 101(4):311-20. PubMed ID: 11355302
[TBL] [Abstract][Full Text] [Related]
11. Genetic pathways to glioblastomas.
Ohgaki H
Neuropathology; 2005 Mar; 25(1):1-7. PubMed ID: 15822813
[TBL] [Abstract][Full Text] [Related]
12. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.
Boström J; Cobbers JM; Wolter M; Tabatabai G; Weber RG; Lichter P; Collins VP; Reifenberger G
Cancer Res; 1998 Jan; 58(1):29-33. PubMed ID: 9426052
[TBL] [Abstract][Full Text] [Related]
13. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
[TBL] [Abstract][Full Text] [Related]
14. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.
Barresi V; Simbolo M; Mafficini A; Martini M; Calicchia M; Piredda ML; Ciaparrone C; Bonizzato G; Ammendola S; Caffo M; Pinna G; Sala F; Lawlor RT; Ghimenton C; Scarpa A
Acta Neuropathol Commun; 2021 Dec; 9(1):200. PubMed ID: 34952640
[TBL] [Abstract][Full Text] [Related]
15. p53 mutations versus EGF receptor expression in giant cell glioblastomas.
Peraud A; Watanabe K; Plate KH; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1997 Nov; 56(11):1236-41. PubMed ID: 9370234
[TBL] [Abstract][Full Text] [Related]
16. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
Ohgaki H; Kleihues P
J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
[TBL] [Abstract][Full Text] [Related]
17. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
18. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
[TBL] [Abstract][Full Text] [Related]
19. Genetic profile of the giant cell glioblastoma.
Peraud A; Watanabe K; Schwechheimer K; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1999 Feb; 79(2):123-9. PubMed ID: 10068201
[TBL] [Abstract][Full Text] [Related]
20. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
Andrews C; Prayson RA
Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
